Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $32.23 in the last session, down -7.84% from day before closing price of $34.97. In other words, the price has decreased by -$7.84 from its previous closing price. On the day, 5.74 million shares were traded.
Ratios:
We take a closer look at BBIO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.67 and its Current Ratio is at 4.67.
On September 04, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $46.Piper Sandler initiated its Overweight rating on September 04, 2024, with a $46 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 06 ’25 when HANNAH A VALANTINE bought 12,875 shares for $32.58 per share.
KKR Genetic Disorder L.P. bought 6,000,000 shares of BBIO for $209,820,000 on Mar 05 ’25. On Feb 25 ’25, another insider, STEPHENSON BRIAN C, who serves as the CFO and Treasurer of the company, sold 8,500 shares for $33.19 each. As a result, the insider received 282,115 and left with 102,464 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 27.62.
Stock Price History:
Over the past 52 weeks, BBIO has reached a high of $39.47, while it has fallen to a 52-week low of $21.62. The 50-Day Moving Average of the stock is -1.74%, while the 200-Day Moving Average is calculated to be 15.62%.
Shares Statistics:
A total of 190.04M shares are outstanding, with a floating share count of 149.23M. Insiders hold about 21.54% of the company’s shares, while institutions hold 76.15% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is -$0.83, with high estimates of -$0.75 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$3.42 and -$3.97 for the fiscal current year, implying an average EPS of -$3.74. EPS for the following year is -$3.17, with 3.0 analysts recommending between -$2.71 and -$3.7.
Revenue Estimates
According to 13 analysts, the current quarter’s revenue is expected to be $45.72M. It ranges from a high estimate of $91.8M to a low estimate of $8M. As of the current estimate, BridgeBio Pharma Inc’s year-ago sales were $211.12MFor the next quarter, 13 analysts are estimating revenue of $43.93M. There is a high estimate of $110M for the next quarter, whereas the lowest estimate is $13M.
A total of 17 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $589M, while the lowest revenue estimate was $141.06M, resulting in an average revenue estimate of $238.59M. In the same quarter a year ago, actual revenue was $221.9MBased on 14 analysts’ estimates, the company’s revenue will be $496.18M in the next fiscal year. The high estimate is $763.11M and the low estimate is $225.48M.
